Genomic Health to Participate in Therapeutic Workshop at BIO InvestorForum 2006
Posted on: Thursday, 12 October 2006, 12:00 CDT
REDWOOD CITY, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced that Kim Popovits, Genomic Health's Chief Operating Officer, will participate in a panel discussion titled "Molecular Diagnostics -- Today and in the Future" at the BIO InvestorForum 2006 in San Francisco, CA on Thursday, October 19 at 8:30 AM Pacific Time.
To access the webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com/. An archived replay will be available for three months beginning 24 hours after the presentation.
About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com/.
Genomic Health, Inc.
CONTACT: Brad Cole of Genomic Health, Inc., +1-650-569-2281, orinvestors@genomichealth.com; or Emily Faucette of WeissComm Partners,+1-415-946-1066, or media@genomichealth.com, for Genomic Health, Inc.
Web site: http://www.genomichealth.com/
Source: PRNewswire-FirstCall
Related Articles
- Genomic Health Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential for Accurate Recurrence Risk Assessment in Early-Stage Breast Cancer Patients
- Genomic Health's Oncotype DX(R) Colon Cancer Test Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients
- Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
- Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
- Genomic Health Announces 'Early Release' Publication of NSABP Study Confirming Oncotype DX Predicts Chemotherapy Benefit in Certain Breast Cancer Patients; Study Findings Pave Way for Landmark NCI TAILORx Trial
- Medicare Contractor Establishes Reimbursement Coverage Policy for Genomic Health's Oncotype DX(TM) Breast Cancer Test
- Genomic Health Announces Study Results Demonstrating Oncotype DX(TM)'s Ability to Quantify Risk for Local and Regional Breast Cancer Recurrence
- Genomic Health Announces Study Results Demonstrating Oncotype DX(TM) Changed Adjuvant Treatment Approach for 25 Percent of Early-Stage Breast Cancer Patients
- Genomic Health Announces Oncotype DX(TM) Study Results to Be Presented at 28th Annual San Antonio Breast Cancer Symposium
- The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health, Inc. Announce Positive Study Results Demonstrating Oncotype DX Genomic Breast Cancer Assay Predicts Chemotherapy Response
 |
 |
User Comments (0)
RSS Feeds